UMIN ID: UMIN000000591
Registered date:15/02/2007
Study of pharmacokinetics and the best way of administration of gefitinib for treated lung adenocarcinoma
Basic Information
| Recruitment status | |
|---|---|
| Health condition(s) or Problem(s) studied | Lung adenocarcinoma |
| Date of first enrollment | 2006/10/01 |
| Target sample size | 15 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | 250mg of gefitinib, every other day. 250mg of gefitinib everyday, every other week. |
Outcome(s)
| Primary Outcome | Tolerance |
|---|---|
| Secondary Outcome | Pharmacokinetics of gefitinib Response rate |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 80years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | severe complication pregnant diarrhea current smoker |
Related Information
| Primary Sponsor | International madical center of Japan |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Japan Foundation for the Promotion of International Medical Research Cooperation |
| Secondary ID(s) |
Contact
| public contact | |
| Name | |
| Address | Japan |
| Telephone | |
| shirano@imcj.hosp.go.jp | |
| Affiliation | International madical center of Japan Respiratory medicine |
| scientific contact | |
| Name | Satoshi Hirano |
| Address | 1-21-1, Toyama, Shinjuku-ku, Tokyo, Japan, 162-8655 Japan |
| Telephone | |
| Affiliation | International madical center of Japan Respiratory medicine |